Oxford BioDynamics has raised £3.6 million in a share placing. The listed biotechnology company is developing targeted clinical diagnostic tests including a severity test for COVID-19. The group, which recently moved into a purpose-built 24,000 sq. ft headquarters in Oxford, has been backed by US-based healthcare fund Armistice Capital Master Fund at a subscription price of … Continue reading Oxford BioDynamics share placing to boost COVID, cancer tests